Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de la terapia combinada de Amivantamab y Olomorasib en participantes con cáncer de pulmón de células no pequeñas metastásico (KaRAnaSa)

2 de noviembre de 2026 actualizado por: Janssen Research & Development, LLC

Un Estudio de Fase 1/2 que Evalúa la Seguridad y Eficacia de la Terapia Combinada de Amivantamab y Olomorasib en el Cáncer de Pulmón de Células No Pequeñas Metastásico

The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose [RP2CD]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation [change] in the kirsten rat sarcoma viral oncogene homolog [KRAS] gene in tumor cells in which glycine [G] at position 12 is replaced with cystine [C]).

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Ontario
      • Toronto, Ontario, Canadá, M5G 2M9
        • Reclutamiento
        • Princess Margaret Hospital
      • Seoul, Corea del Sur, 05505
        • Reclutamiento
        • Asan Medical Center
      • Seoul, Corea del Sur, 06351
        • Reclutamiento
        • Samsung Medical Center
      • Seoul, Corea del Sur, 03722
        • Reclutamiento
        • Severance Hospital Yonsei University Health System
    • New York
      • New York, New York, Estados Unidos, 10016
        • Reclutamiento
        • New York University Langone Medical Center
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Reclutamiento
        • Virginia Cancer Specialists
      • Guangzhou, Porcelana, 510060
        • Reclutamiento
        • The First Affiliated Hospital Sun Yat sen University
      • Harbin, Porcelana, 150000
        • Reclutamiento
        • Harbin medical university cancer hospital
      • Shanghai, Porcelana, 310000
        • Reclutamiento
        • Shanghai East Hospital
      • Ankara, Turquía (Türkiye), 06620
        • Reclutamiento
        • Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
      • Istanbul, Turquía (Türkiye), 34010
        • Reclutamiento
        • Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
      • Çankaya, Turquía (Türkiye), 06800
        • Reclutamiento
        • Ankara Bilkent Sehir Hastanesi

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion criteria:

  • Participant must have histologically or cytologically confirmed metastatic NSCLC characterized by a KRAS G12C mutation at the time of enrollment. For Phase 1: Participant must have progressed on or after, or have intolerance to, platinum-based chemotherapy and Programmed Death-Ligand 1 (PD-L1)-targeted immunotherapy given in combination or sequentially. Receipt of additional lines of prior therapy is permitted. Progression must have occurred on or after the most recent line of systemic anticancer therapy. For Phase 2: Participant must have progressed on or after platinum-based chemotherapy and PD-L1-targeted immunotherapy given in combination or sequentially. Progression must have occurred on or after the most recent line of systemic anticancer therapy. Receipt of additional lines of prior therapy is not permitted
  • Participant must have at least 1 measurable lesion, according to RECIST version.1.1, that has not been previously irradiated
  • May have brain metastases only if previously definitively, locally treated, and participant is clinically stable and asymptomatic for greater than (>) 2 weeks and is off or receiving low-dose corticosteroid treatment for at least 2 weeks prior to start of study treatment
  • Can have a prior or concurrent second malignancy (other than the disease under study) with natural history or treatment course that is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion criteria:

  • Participant has history of uncontrolled illness
  • Suspected or known allergies, hypersensitivity, or intolerance to amivantamab excipients or olomorasib excipients
  • Medical history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
  • Presence of primary driver mutations (epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], mesenchymal-epithelial transition [MET], human epidermal growth factor receptor 2 [HER2], ROS1, neurotrophic tyrosine receptor kinase [NTRK], B-Raf proto-oncogene [BRAF], rearranged during Transfection [RET], neuroblastoma RAS viral oncogene homolog [NRAS], and other KRAS mutations besides G12C) as determined by local genomic testing
  • Prior treatment with any KRAS inhibitor

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Phase 1: Combination Dose Selection

Participants will receive amivantamab along with olomorasib to determine the RP2CD of the combination therapy until disease progression, significant toxicity, or until another criterion for discontinuation of study treatment is met. Eligible participants may have the option to transfer to a long-term extension (LTE) phase for continued access to study treatments.

Amivantamab will be administered.

Otros nombres:
  • JNJ-61186372
  • RYBREVANT

Olomorasib will be administered.

Otros nombres:
  • LY3537982
Experimental: Phase 2: Expansion

Participants will receive amivantamab and olomorasib combination therapy at the RP2CD determined in Phase 1 until disease progression, significant toxicity, or until another criterion for discontinuation of study treatment is met. Eligible participants may have the option to transfer to LTE phase for continued access to study treatments.

Amivantamab will be administered.

Otros nombres:
  • JNJ-61186372
  • RYBREVANT

Olomorasib will be administered.

Otros nombres:
  • LY3537982

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Phase 1: Number of Participants with Adverse Events (AEs) by Severity
Periodo de tiempo: Up to approximately 3 years 2 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An assessment of severity grade will be made by the investigator according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 defined as follows: Grade 1 (mild; asymptomatic or mild symptoms; intervention not indicated); Grade 2 (moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living [ADL]); Grade 3 (severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 (life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to adverse event).

Up to approximately 3 years 2 months
Phase 1: Number of Participants with Dose-Limiting Toxicities (DLTs)
Periodo de tiempo: Up to approximately 3 years 2 months

DLT is defined as drug related adverse events and includes unacceptable non-hematologic toxicity, hematologic toxicity, pulmonary toxicity, or elevations in hepatic enzymes suggestive of drug-induced liver injury of Grade 3 or higher. Toxicities will be graded for severity according to the NCI-CTCAE, version 5.0.

Up to approximately 3 years 2 months
Phase 2: Confirmed Objective Response Rate (ORR)
Periodo de tiempo: Up to approximately 3 years 2 months

ORR is defined as the percentage of participants who achieve either a confirmed partial response (PR) or complete response (CR), using Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 by investigator review. Confirmatory analysis may be performed using Blinded Independent Central Review (BICR).

Up to approximately 3 years 2 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants with Adverse Events (AEs) by Severity
Periodo de tiempo: Up to approximately 3 years 2 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An assessment of severity grade will be made by the investigator according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 defined as follows: Grade 1 (mild; asymptomatic or mild symptoms; intervention not indicated); Grade 2 (moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living [ADL]); Grade 3 (severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 (life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to adverse event).

Up to approximately 3 years 2 months
Number of Participants with Abnormalities in Clinical Laboratory Parameters
Periodo de tiempo: Up to approximately 3 years 2 months

Number of participants with abnormalities in clinical laboratory values (which includes serum chemistry, hematology, coagulation, urinalysis, and serology) will be reported.

Up to approximately 3 years 2 months
Phase 2: Duration of Response (DoR)
Periodo de tiempo: Up to approximately 3 years 2 months

DoR is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death from any case, whichever comes first, for participant who have PR or CR according to RECIST v1.1 by investigator review.

Up to approximately 3 years 2 months
Phase 2: Disease Control Rate (DCR)
Periodo de tiempo: Up to approximately 3 years 2 months

DCR is defined as the percentage of participants who achieve a PR, CR, or stable disease using RECIST v1.1.

Up to approximately 3 years 2 months
Phase 2: Progression-Free Survival (PFS)
Periodo de tiempo: Up to approximately 3 years 2 months

PFS is defined as the time from first dose date until the date of disease progression or death, whichever comes first, based on investigator assessment using RECIST v1.1 by investigator review.

Up to approximately 3 years 2 months
Phase 2: Overall Survival (OS)
Periodo de tiempo: Up to approximately 3 years 2 months

OS is defined as the time from the date of administration of the first dose of study treatment until the date of death due to any cause.

Up to approximately 3 years 2 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de marzo de 2026

Finalización primaria (Estimado)

30 de noviembre de 2028

Finalización del estudio (Estimado)

30 de abril de 2029

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2025

Publicado por primera vez (Actual)

12 de noviembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 61186372PANSC2004
  • 61186372PANSC2004 (Otro identificador: Janssen Research & Development, LLC)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir